Close Menu


Researchers from the BGI and King Abdulaziz City for Science and Technology announced today that they have sequenced the Arabian camel genome.

BGI plans to build sequencing facilities at both locations. It also wants to open branches in Southeast Asia and Australia.

BGI will recruit between 20 and 50 people during the first year of the Copenhagen HQ — to be called BGI Europe — then establish a sequencing platform allowing for the additional hiring of between 50 and 100 people.

The scientists will sequence 100 genomes on the HiSeq 2000 as part of a consortium that aims to sequence 10,000 vertebrate species.

As part of an international effort to sequence 10,000 vertebrate genomes, researchers at BGI are getting ready to sequence 100 vertebrate species over the next year or two.

The new sequence data includes 156 new insertions corresponding to novel exons and noncoding regions. The researchers also compared their data to a next-generation sequence and de novo assembled genome, highlighting the advantages and limitations of the newer technology.

BGI will use Agilent's SureSelect solution-based target enrichment product, the Bravo automated liquid-handling platform, and the 2100 Bioanalyzer.

The study, which besides BGI involves researchers at the University of Florida and at the University of Maryland at College Park, is part of BGI's recently launched project to sequence 1,000 plant and animal reference genomes over the next two years.

Chinese and American researchers plan to sequence and compare the genomes of the sea slug, Elysia chlorotica, and Vaucheria litorea, an algal species from which the slug has taken chloroplast biosynthesis genes.

The sequencing was done at BGI-Shenzen and marked the first step in the four-year MetaHIT project, which aims to create a comprehensive gene catalog of the gut microbiome in order to understand how the bacteria that live in human intestines are related to disease.


A Harvard-led team reprogrammed DNA methylation patterns of mice with eye problems to restore their sight, AFP reports.

A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.

The New York Times reports Moderna is planning a clinical trial of its SARS-CoV-2 vaccine in children.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.